HydraFacial v. Advanced Aesthetics Services — ITC 337-TA-1416 Withdrawn
HydraFacial LLC brought a Section 337 complaint before the US International Trade Commission against Advanced Aesthetics Services LLC, asserting two patents covering console systems and methods for skin treatment. The complaint was withdrawn after 217 days, ending the investigation before any merits ruling was issued.
HydraFacial’s ITC skin-device action ends on withdrawal
On 6 August 2024, HydraFacial LLC — formerly Edge Systems LLC — filed ITC Investigation No. 337-TA-1416 against Advanced Aesthetics Services LLC, asserting infringement of US11865287B2 (console system for the treatment of skin) and US9550052B2 (devices and methods for treating skin). The action was brought before the United States International Trade Commission under Section 337 of the Tariff Act, which empowers the ITC to issue exclusion orders barring infringing imports.
The investigation closed on 11 March 2025 — 217 days after filing — when HydraFacial withdrew its complaint. The participant disposition is recorded as ‘Complaint Withdrawn’ and the basis of termination as ‘Case Withdrawn.’ No violation finding, limited exclusion order, or cease-and-desist order was issued. Whether the withdrawal reflects an underlying settlement, a licence agreement, or a strategic recalibration is not disclosed in the public record.
A withdrawal at this stage of an ITC proceeding — before an Administrative Law Judge issues an Initial Determination — is not unusual when parties reach a commercial resolution outside the formal process. The relatively compact 217-day timeline, combined with the absence of any procedural contest on the record, suggests the dispute may have been resolved bilaterally. The precise terms, if any, remain confidential, leaving the enforceability of the two asserted patents against the broader market unresolved by this proceeding.
Filing to Case Withdrawn in 217 days
217 days — resolved before full ITC evidentiary hearing stage
Complaint withdrawn: what the ITC case closure means for both parties
What ‘Complaint Withdrawn’ means at the ITC
At the ITC, a complainant may withdraw its complaint at any stage, causing the investigation to terminate without a merits ruling. No finding of Section 337 violation is made, meaning no exclusion order or cease-and-desist order issues. The withdrawal is procedurally neutral — it does not constitute an admission of invalidity or non-infringement by either party.
No violation findingPublic record is silent on whether a deal was struck
ITC complaint withdrawals may follow a confidential settlement, licence, or consent agreement — or may reflect the complainant’s independent decision to discontinue. The public record does not specify which applies here. Practitioners should not infer that HydraFacial’s patent rights were conceded or that Advanced Aesthetics Services obtained a licence; the terms are simply not disclosed.
Terms undisclosedHydraFacial retains its patents and ITC re-filing option
Withdrawal does not exhaust HydraFacial’s enforcement options. The two asserted patents — US11865287B2 and US9550052B2 — remain in force. HydraFacial could re-file an ITC complaint or pursue parallel district court infringement claims against the same or other respondents. The withdrawal may have been tactically motivated by a commercial resolution that was preferable to the cost and uncertainty of a full ITC trial.
Patents remain enforceableNo exclusion order — but patent risk persists for the sector
Advanced Aesthetics Services avoids an import ban and cease-and-desist order, but the patents are not invalidated by this outcome. Other aesthetic device companies operating in the same space — particularly those importing skin treatment console systems — should treat HydraFacial’s continued patent portfolio as an active risk factor and consider freedom-to-operate analysis against both asserted patents.
No IP clearance grantedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | HydraFacial LLC f/k/a Edge Systems LLC | Company | Aesthetic device manufacturer — holder of US11865287B2 and US9550052B2Search in Eureka ↗ |
| Defendant | Advanced Aesthetics Services LLC | Company | Aesthetic services provider accused of importing or selling infringing skin treatment devicesSearch in Eureka ↗ |
| Plaintiff counsel | Stephanie Roberts | Attorney | Counsel for HydraFacial LLC f/k/a Edge Systems LLCSearch in Eureka ↗ |
| Plaintiff law firm | Morgan, Lewis & Bockius, LLP | Law Firm | Representing HydraFacial LLC f/k/a Edge Systems LLCSearch in Eureka ↗ |
| Defendant counsel | Matthew Duescher | Attorney | Counsel for Advanced Aesthetics Services LLCSearch in Eureka ↗ |
| Defendant law firm | Foster, Murphy, Altman & Nickel PC | Law Firm | Representing Advanced Aesthetics Services LLCSearch in Eureka ↗ |
| Presiding judge | Judge MaryJoan McNamara | Judge | United States International Trade CommissionSearch in Eureka ↗ |
Official order — verbatim text
The disposition records ‘Complaint Withdrawn’ as the participant outcome, with ‘Case Withdrawn’ as the basis of termination. This phrasing confirms the investigation ended on the complainant’s own initiative — not through an ALJ or Commission ruling. No Section 337 violation was found, and no remedial orders issued. The record is silent on any accompanying agreement, meaning the legal status of both asserted patents vis-à-vis Advanced Aesthetics Services is formally unresolved by this proceeding.
US11865287B2 & US9550052B2 — skin treatment console systems and devices
US11865287B2 (application no. US18/094884) protects a console system for the treatment of skin — likely covering the integrated hardware architecture central to HydraFacial’s device platform. US9550052B2 (application no. US14/698673) covers devices and methods for treating skin, an earlier foundational patent in the same technology family. Both patents sit within the hydrodermabrasion and vortex-extraction domain that HydraFacial has built its commercial identity around.
For the aesthetic device sector, these patents collectively represent a defensive moat around the console-and-tip system architecture popularised by HydraFacial’s flagship product. The combination of a system-level claim (US11865287B2) and a method-plus-device claim (US9550052B2) creates overlapping coverage that complicates design-around efforts for competitors. Any company developing or importing a multi-function skin treatment console should assess both patents for claim overlap before commercialisation.
Should you run an FTO against US11865287B2 and US9550052B2?
R&D teams developing console-based skin treatment devices — particularly those incorporating hydrodermabrasion, vortex-extraction, or multi-tip delivery systems — should treat these two patents as priority targets for freedom-to-operate analysis. The ITC filing signals active enforcement intent, and the absence of a merits ruling means neither patent has been tested for validity or scope in this proceeding. Importers and OEM partners face the greatest immediate exposure given the ITC’s import-exclusion remedy.
PatSnap Eureka’s FTO Search Agent can map the claims of US11865287B2 and US9550052B2 against your product architecture, identify prior art that could support invalidity arguments, and surface any continuation or divisional applications in the same family that may extend coverage. Running this analysis before finalising a product design or import arrangement is substantially less costly than responding to an ITC complaint.
Run a freedom-to-operate analysis on US11865287B2 to assess your product’s exposure
Run FTO in Eureka →Similar ITC Section 337 cases in aesthetic and medical skin-treatment devices
Explore related ITC and district court patent actions involving skin treatment console systems, hydrodermabrasion devices, and aesthetic technology IP enforced before the USITC.
What this case signals for the aesthetic device IP landscape
HydraFacial’s ITC filing underscores the use of trade remedies to defend premium skin-treatment device IP against lower-cost market entrants.
ITC Section 337 remains a potent first strike for device OEMs
Filing at the ITC — rather than district court — signals HydraFacial’s intent to seek import relief, not just damages. The threat of an exclusion order frequently accelerates resolution. Aesthetic device companies sourcing hardware from overseas should map their supply chains against HydraFacial’s patent portfolio before importing.
Withdrawal without prejudice keeps enforcement leverage intact
Because no merits ruling was issued, HydraFacial’s two asserted patents emerge from this proceeding unchallenged and unweakened. The company retains full standing to re-assert both patents in future ITC or district court actions, making this withdrawal a pause rather than an exit from enforcement.
HydraFacial v Advanced — key questions answered
HydraFacial LLC filed a Section 337 complaint at the ITC on 6 August 2024 asserting US11865287B2 and US9550052B2 against Advanced Aesthetics Services LLC. The complaint was withdrawn on 11 March 2025 — 217 days after filing — without any violation finding, exclusion order, or cease-and-desist order being issued.
No. A complaint withdrawal at the ITC does not constitute a ruling on patent validity or infringement. US11865287B2 and US9550052B2 remain in force and HydraFacial retains full standing to assert them in future ITC or district court proceedings against any party.
It means the complainant voluntarily terminated the investigation before an Administrative Law Judge issued an Initial Determination. No Section 337 violation finding is made, and no remedial orders — such as a limited exclusion order or cease-and-desist order — are issued. The basis of termination is procedural, not substantive.
HydraFacial asserted two patents: US11865287B2 covering a console system for the treatment of skin, and US9550052B2 covering devices and methods for treating skin. Both patents relate to the hydrodermabrasion and vortex-extraction technology associated with HydraFacial’s core product platform.
Yes. A withdrawal without a merits ruling does not bar HydraFacial from filing a new ITC complaint or pursuing district court infringement claims. The withdrawn investigation creates no estoppel or res judicata effect on the patents’ enforceability, subject to any confidential agreement that may have accompanied the withdrawal.
PatSnap Eureka searches patents and litigation data to answer instantly.